Benitec Biopharma (NASDAQ:BNTC) Receives “Buy” Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of Benitec Biopharma (NASDAQ:BNTC) in a research note issued to investors on Friday morning,Benzinga reports. HC Wainwright currently has a $28.00 price objective on the biotechnology company’s stock.

BNTC has been the topic of a number of other reports. Baird R W raised shares of Benitec Biopharma to a “strong-buy” rating in a research report on Thursday, December 12th. Guggenheim reissued a “buy” rating and set a $17.00 target price on shares of Benitec Biopharma in a research report on Tuesday, December 3rd. Finally, Robert W. Baird assumed coverage on shares of Benitec Biopharma in a research report on Friday, December 13th. They set an “outperform” rating and a $30.00 target price on the stock. Seven research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $24.43.

Benitec Biopharma Price Performance

BNTC opened at $11.30 on Friday. The company’s 50 day simple moving average is $11.29 and its 200 day simple moving average is $10.33. Benitec Biopharma has a 1 year low of $3.28 and a 1 year high of $13.29.

Benitec Biopharma (NASDAQ:BNTC) last announced its quarterly earnings results on Friday, February 14th. The biotechnology company reported ($0.36) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.55) by $0.19. As a group, sell-side analysts anticipate that Benitec Biopharma will post -1.48 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, Director Suvretta Capital Management, L bought 42,000 shares of the firm’s stock in a transaction that occurred on Tuesday, December 3rd. The stock was purchased at an average price of $9.60 per share, for a total transaction of $403,200.00. Following the transaction, the director now directly owns 7,957,365 shares of the company’s stock, valued at approximately $76,390,704. This represents a 0.53 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 1.30% of the company’s stock.

Hedge Funds Weigh In On Benitec Biopharma

Large investors have recently made changes to their positions in the business. Acuta Capital Partners LLC bought a new position in shares of Benitec Biopharma during the 3rd quarter valued at about $274,000. Ameriprise Financial Inc. boosted its position in shares of Benitec Biopharma by 138.4% during the 4th quarter. Ameriprise Financial Inc. now owns 35,476 shares of the biotechnology company’s stock valued at $448,000 after purchasing an additional 20,597 shares in the last quarter. 683 Capital Management LLC bought a new position in shares of Benitec Biopharma during the 4th quarter valued at about $452,000. Northern Trust Corp boosted its position in shares of Benitec Biopharma by 54.2% during the 4th quarter. Northern Trust Corp now owns 38,200 shares of the biotechnology company’s stock valued at $482,000 after purchasing an additional 13,425 shares in the last quarter. Finally, MYDA Advisors LLC bought a new position in shares of Benitec Biopharma during the 4th quarter valued at about $632,000. Institutional investors own 52.19% of the company’s stock.

Benitec Biopharma Company Profile

Benitec Biopharma Inc, a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy.